VOYAH FREE tillgänglig i Europa och VOYAH Showroom öppnades
"Den intelligenta elektriska SUV:n VOYAH FREE tillgänglig i Europa efter att ha sålt bra på den kinesiska marknaden i nästan ett år. Den 11 juni 2022 öppnades VOYAH Showroom på Klingenberggt. 7 i centrala Oslo, Norge. Över 100 personer, inklusive gäster, media och kundrepresentanter, samlades för att bevittna öppnandet av verksamheten denna dag, under vilken "den intelligenta elektriska SUV:en på prestandanivå" VOYAH FREE och "den elektriska lyxiga flaggskepps-MPV:n" VOYAH Dream debuterade tillsammans.
Detta pressmeddelande använder multimedia. Se den fullständiga versionen här: https://www.businesswire.com/news/home/20220616005592/sv/
Det första utomeuropeiska VOYAH Showroom ligger i centrala Oslo, Norge, och VOYAH FREE presenteras i Norge. (Photo: Business Wire)
Lu Fang, VD och teknikchef för VOYAH Automobile, säger: "VOYAH, ett varumärke för ny energi av hög kvalitet som lanserats av Dongfeng Motor Group, har åtagit sig att perfekt integrera körprestanda och intelligent teknik för att forma det globala inflytandet för kinesiska varumärken. I framtiden kommer VOYAH att utnyttja Dongfengs kraftfulla utländska resurser och innovativa teknik och affärsmodell för att erbjuda en ny upplevelse av intelligenta elfordon."
Torje Aleksander Sulland, vd för Electric Way, en norsk distributör av VOYAH, säger: "VOYAH:s vackra karosslinjer, unika designkoncept och den utforskningsanda som finns i den orientaliska berättelsen om den stora hökens vingar som breder ut sina vingar är något som folk tycker om. VOYAH FREE:s kraftfulla prestanda, ultimata körglädje, säkerhetsteknik och högkvalitativa elektriska upplevelse gör också körningen säker och sund. Vi tror att VOYAH kommer att bli omtyckt av de nordiska folken."
VOYAH FREE, den första modellen från VOYAH Automobile som exporteras till Europa, är kompatibel med Norges lokala geografiska klimat, miljöskyddskoncept och marknadens efterfrågan på avancerade elfordon. VOYAH FREE har en effektfördel som är jämförbar med super-running, med stabil batteriprestanda. Dessutom har den 100 mm justerbar luftfjädring uppåt och nedåt och intelligent fyrhjulsdrift för hela bilen. Den matchar de fyra körlägena "ekonomi, komfort, hög effektivitet och utflykt", anpassar sig till komplexa vägförhållanden och tillfredsställer norska användare på olika sätt.
Det första utomeuropeiska VOYAH Showroom har genom medvetna förberedelser och hårt arbete fått VOYAH:s varumärkeskoncept, och genom den geniala integrationen av livets textur, framtida teknik och kinesiska element förkroppsligar det "temperaturkänslig vetenskaplighet". Det rapporteras att norska användare kan boka tid för provkörning av VOYAH FREE strax efter öppnandet av VOYAH Showroom i Oslo. Under fjärde kvartalet i år kommer den norska marknaden att se massleverans av nya bilar.
För att se det här innehållet från cts.businesswire.com måste du ge ditt medgivande sidans topp.
Se källversionen på businesswire.com: https://www.businesswire.com/news/home/20220616005592/sv/
Contact information
China Dongfeng Motor Industry Imp. & Exp. Co. Ltd
Cheng Hua
chenghua@dfmc.com.cn
+8615172529276
http://www.dongfeng-global.com/
https://www.facebook.com/VoyahGlobal
https://www.facebook.com/DongfengMotorCorporationGlobal
https://www.tiktok.com/@dfmotor
Om
Följ Business Wire
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.
Besök vårt pressrum